Polymorphisms in GRIA1 gene are a risk factor for asparaginase hypersensitivity during the treatment of childhood acute lymphoblastic leukemia

Leukemia and Lymphoma

Volumn 56, Issue 11, 2015, Pages 3103-3108

  Rajić, Vladan ^a   Debeljak, Maruša ^b   Goričar, Katja ^c   Jazbec, Janez ^a  

^a UNIVERSITY CHILDREN S HOSPITAL   (Slovenia)

^b UNIVERSITY MEDICAL CENTRE LJUBLJANA   (Slovenia)

^c UNIVERSITY OF LJUBLJANA   (Slovenia)

Author keywords

allergy and hypersensitivity; Genetic and other predisposing conditions; lymphoid leukemia

Indexed keywords

ASPARAGINASE; CORTICOSTEROID; AMPA RECEPTOR; ANTINEOPLASTIC AGENT; GLUTAMATE RECEPTOR IONOTROPIC, AMPA 1;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; ADVERSE DRUG REACTION; AGE; ARTICLE; CHILD; CHILDHOOD LEUKEMIA; DRUG WITHDRAWAL; EVENT FREE SURVIVAL; FEMALE; GENDER; GENE; GENETIC ASSOCIATION; GRIA1 GENE; HUMAN; HYPERSENSITIVITY; IMMUNOPHENOTYPING; LYMPHOBLASTOMA; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; SEX DIFFERENCE; SINGLE NUCLEOTIDE POLYMORPHISM; ALLELE; COHORT ANALYSIS; COMPLICATION; DRUG HYPERSENSITIVITY; GENE FREQUENCY; GENETIC PREDISPOSITION; GENETICS; GENOTYPE; INFANT; MORTALITY; ODDS RATIO; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PRESCHOOL CHILD; YOUNG ADULT;

ADOLESCENT; ALLELES; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ASPARAGINASE; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; DRUG HYPERSENSITIVITY; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; INFANT; MALE; ODDS RATIO; POLYMORPHISM, SINGLE NUCLEOTIDE; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; RECEPTORS, AMPA; YOUNG ADULT;

EID: 84947793715     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2015.1020802     Document Type: Article

References (55)

1. Tallal L, Tan C, Oettgen H, et al. E. coli L-asparaginase in the treatment of leukemia and solid tumors in 131 children. Cancer 1970; 25: 306-320.
2. Muller HJ, Boos J. Use of L-asparaginase in childhood ALL. Crit Rev Oncol Hematol 1998; 28: 97-113.
3. Pui CH, Evans WE. Treatment of acute lymphoblastic leukemia. N Engl J Med 2006; 354: 166-78.
4. Rabin KR, Poplack DG. Management strategies in acute lymphoblastic leukemia. Oncology (Williston Park) 2011; 25: 328-35.
5. Pieters R, Hunger S, Boos J, et al. L-asparaginase treatment in acute lymphoblastic leukemia. Cancer 2011; 117: 238-249.
6. Rizzari C, Conter V, Starý J, Colombini A, Moericke A, Schrappe M. Optimizing asparaginase therapy for acute lymphoblastic leukemia. Curr Opin Oncol 2013; 25 Suppl 1: S1-9.
7. Woo MH, Hak LJ, Storm MC, Sandlund JT, Ribeiro RC, et al. Hypersensitivity or development of antibodies to asparaginase does not impact treatment outcome of childhood acute lymphoblastic leukemia. J Clin Oncol 2000; 18: 1525-32.
8. Albertsen BK, Schrøder H, Jakobsen P, Avramis VI, Müller HJ, Schmiegelow K, Carlsen NT. Antibody formation during intravenous and intramuscular therapy with Erwinia asparaginase. Med Pediatr Oncol 2002; 38: 310-6.
9. Capizzi RL, Bertino JR, Skeel RT, Creasey WA, Zanes R, Olayon C, et al. L-asparaginase: clinical, biochemical, pharmacological, and immunological studies. Ann Intern Med 1971; 74: 893-901.
10. Pieters R, Hunger SP, Boos J, Rizzari C, Silverman L, Baruchel A, Pui CH. L-asparaginase treatment in acute lymphoblastic leukemia: A focus on Erwinia asparaginase. Cancer 2011; 117: 238-249.
11. Chen SH, Pei D, Yang W, Cheng C, Jeha S, et al. Genetic variations in GRIA1 on chromosome 5q33 related to asparaginase hypersensitivity. Clin Pharmacol Ther 2010; 88: 191-6.
12. Traynelis SF, Wollmuth LP, McBain CJ, Menniti FS, Vance KM, et al. Glutamate receptor ion channels: structure, regulation, and function. Pharmacol Rev 2010; 62: 405-96.
13. Nakanishi N, Shneider NA, Axel R. A family of glutamate receptor genes: evidence for the formation of heteromultimeric receptors with distinct channel properties. Neuron 1990; 5: 569-581.
14. Woo MH, Hak LJ, Storm MC, Sandlund JT, Ribeiro RC, Rivera GK, Relling MV. Hypersensitivity or development of antibodies to asparaginase does not impact treatment outcome of childhood acute lymphoblastic leukemia. J Clinical Oncol 2000; 18: 1525-1532.
15. Nakanishi S, Masu M. Molecular diversity and functions of glutamate receptors. Annu Rev Biophys Biomol Struct 1994; 23: 319-48.
16. Nakagawa T. The biochemistry, ultrastructure, and subunit assembly mechanism of AMPA receptors. Mol Neurobiol 2010; 42: 161-84
17. Sommer B, Keinänen K, Verdoorn TA, Wisden W, Burnashev N, et al. Flip and flop: a cell-specific functional switch in glutamate-operated channels of the CNS. Science 1990; 249: 1580-5.
18. Monyer H, Seeburg PH, Wisden W. Glutamate-operated channels: developmentally early and mature forms arise by alternative splicing. Neuron 1991; 6: 799-810.
19. Simpson L, Emeson RB. RNA editing. Ann Rev Neurosci 1996; 19: 27-52.
20. Levite M. Neurotransmitters activate T-cells and elicit crucial functions via neurotransmitter receptors. Curr Opin Pharmacol 2008; 8: 460-71.
21. Franco R, Pacheco R, Lluis C, Ahern GP, OConnell PJ. The emergence of neurotransmitters as immune modulators. Trends Immunol 2007; 28: 400-7.
22. Boldyrev AA, Carpenter DO, Johnson P. Emerging evidence for a similar role of glutamate receptors in the nervous and immune systems. J Neurochem 2005; 95: 913-8.
23. Ganor Y, Besser M, Ben-Zakay N, Unger T, Levite M. Human T-cells express a functional ionotropic glutamate receptor GluR3, and glutamate by itself triggers integrin-mediated adhesion to laminin and fibronectin and chemotactic migration. J. Immunol 2003; 170: 4362-4372.
24. Boldyrev AA, Kazey VI, Leinsoo TA, Mashkina AP, Tyulina OV, et al. Rodent lymphocytes express functionally active glutamate receptors. Biochem Biophys Res Commun 2004; 324: 133-139.
25. Vandebriel RJ. Gene polymorphisms within the immune system that may underlie drug allergy. Naunyn Schmiedebergs Arch Pharmacol 2004; 369: 125-32.
26. Feske S. Ca(2+) influx in T cells: how many ca(2+) channels Front Immunol 2013; 4: 99. doi: 10.3389/fimmu.2013.00099
27. Egebjerg J, Kukekov V, Heinemann SF. Intron sequence directs RNA editing of the glutamate receptor subunit GluR2 coding sequence. Proc Natl Acad Sci USA 1994; 91: 10270-4.
28. Rodriguez S, Gaunt TR, Day INM. Hardy-Weinberg Equilibrium Testing of Biological Ascertainment for Mendelian Randomization Studies. Am J Epidemiol 2009; 169: 505-14. doi: 10.1093/aje/kwn359.
29. Schrappe M, Möricke A, Reiter A, Henze G, Welte K, et al. Key treatment questions in childhood acute lymphoblastic leukemia: results in 5 consecutive trials performed by the ALL-BFM study group from 1981 to 2000. Klin Padiatr 2013; 225 Suppl 1: S62-72.
30. Möricke A, Lauten M, Beier R, Odenwald E, Stanulla M, et al. Prediction of outcome by early response in childhood acute lymphoblastic leukemia. Klin Padiatr 2013; 225 Suppl 1: S50-6. doi: 10.1055/s-0033-1337964.
31. Möricke A, Zimmermann M, Reiter A, Henze G, Schrauder A, et al. Long-term results of five consecutive trials in childhood acute lymphoblastic leukemia performed by the ALL-BFM study group from 1981 to 2000. Leukemia 2010; 24: 265-84. doi: 10.1038/leu.2009.257.
32. Pieters R, Hunger SP, Boos J, Rizzari C, Silverman L, et al. L-asparaginase treatment in acute lymphoblastic leukemia: a focus on Erwinia asparaginase. Cancer 2011; 117: 238-49.
33. Bussolati O, Belletti S, Uggeri J, Gatti R, Orlandini G, DallAsta V, et al. Characterization of apoptotic phenomena induced by treatment with L-asparaginase in NIH3T3 cells. Exp Cell Res 1995; 220: 283-291.
34. Yang L, Panetta JC, Cai X, Yang W, Pei D, et al. Asparaginase may influence dexamethasone pharmacokinetics in acute lymphoblastic leukemia. J Clin Oncol 2008; 26: 1932-9.
35. Silverman LB, Gelber RD, Dalton VK, Asselin BL, Barr R, et al. Improved outcome for children with acute lymphoblastic leukemia: results of Dana-Farber Consortium Protocol 91-01. Blood 2001; 97: 1211-8.
36. Zalewska-Szewczyk B, Andrzejewski W, Młynarski W, Jedrychowska-Dańska K, Witas H, Bodalski J. The anti-asparagines antibodies correlate with L-asparagines activity and may affect clinical outcome of childhood acute lymphoblastic leukemia. Leuk Lymphoma 2007; 48: 931-6.
37. Capizzi RL, Bertino JR, Skeel RT, Creasey WA, Zanes R, Olayon C, et al. L-asparaginase: clinical, biochemical, pharmacological, and immunological studies. Ann Intern Med 1971; 74: 893-901.
38. Appel IM, den, Boer ML, Meijerink JP, Veerman AJ, Reniers NC, Pieters R. Up-regulation of asparagine synthetase expression is not linked to the clinical response L-asparaginase in pediatric acute lymphoblastic leukemia. Blood 2006; 107: 4244-4249.
39. Asselin BL, Whitin JC, Coppola DJ, et al. Comparative pharmacokinetic studies of three asparaginase preparations. J Clin Oncol 1993; 11: 1780-1786.
40. Raetz EA, Salzer WL. Tolerability and efficacy of L-asparaginase therapy in pediatric patients with acute lymphoblastic leukemia. J Pediatr Oncol 2010; 32: 554-563.
41. Zalewska-Szewczyk B, Gach A, Wyka K, et al. The cross-reactivity of antiasparaginase antibodies against different L-asparaginase preparations. Clin Exp Med 2009; 9: 113-116.
42. Boulter J, Hollmann M, O Shea-Greenfield A, Hartley M, Deneris E, et al. Molecular cloningand functional expression of glutamate receptor subunit genes. Science 1990; 249: 1033-1037.
43. Hollmann M, O Shea-Greenfield A, Rogers SW, Heinemann S. Cloning by functional expression of a member of the glutamate receptor family. Nature 1989; 342: 643-648.
44. Keinanen K, Wisden W, Sommer B, Werner P, Herb A, et al. A family of AMPA-selective glutamate receptors. Science 1990; 249: 556-560.
45. Higuchi M, Single FN, Kohler M, Sommer B, Sprengel R, Seeburg PH. RNA editing of AMPA receptor subunit GluR-B: a base-paired intron-exon structure determines position and efficiency. Cell 1993; 75: 1361-1370.
46. Meguro H, Mori H, Araki K, Kushiya E, Kutsuwada T, et al. Functional characterization of a heteromeric NMDA receptor channel expressed from cloned cDNAs. Nature 1992; 357: 70-74.
47. Moriyoshi K, Masu M, Ishii T, Shigemoto R, Mizuno N, Nakanishi S. Molecular cloning and characterization of the rat NMDA receptor. Nature 1991; 354: 31-37.
48. Armstrong N, Sun Y, Chen GQ, Gouaux E. Structure of a glutamate-receptor ligand-binding core in complex with kainate. Nature 1998; 395: 913-917.
49. Greger IH, Akamine P, Khatri L, Ziff EB. Developmentally regulated, combinatorial RNA processing modulates AMPA receptor biogenesis. Neuron 2006; 51: 85-97.
50. Seeburg PH, Hartner J. Regulation of ion channel/neurotransmitter receptor functions by RNA editing. Curr Opin Neurobiol 2003; 13: 279-83.
51. Pacheco R, Gallart T, Lluis C, Franco R. Role of glutamate on T-cell mediated immunity. J Neuroimmunol 2007; 185: 9-19.
52. Barbon A, Barlati S. Glutamate receptor RNA editing in health and disease. Biochemistry (Mosc) 2011; 76: 882-9.
53. Noguchi E, Shibasaki M, Arinami T, Takeda K, Maki T, et al. Evidence for linkage between asthma/atopy in childhood and chromosome 5q31-q33 in a Japanese population. Am J Respir Crit Care Med 1997; 156: 1390-1393.
54. Beyer K, Nickel R, Freidhoff L, Björkstén B, Huang SK, et al. Association and linkage of atopic dermatitis with chromosome 13q12-14 and 5q31-33 markers. J Invest Dermatol 2000; 115: 906-908.
55. Fernandez CA, Smith C, Yang W, Date M, Bashford D, et al. HLA-DRB1 07:01 is associated with a higher risk of asparaginase allergies. Blood 2014 Jun 26. [Epub ahead of print]